false
0001129928
0001129928
2026-11-19
2026-11-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 19, 2026
Oncolytics Biotech Inc.
(Exact name of registrant as specified in its charter)
| Nevada |
001-38512 |
98-0541667 |
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
4350 Executive Drive, Suite 325
San Diego, CA 92121 |
92121 |
| (Address of principal executive offices) |
(Zip Code) |
| |
|
| (403) 670-7377 |
| (Registrant's telephone number, including area code) |
| |
| N/A |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| |
|
|
|
|
| Common stock, par value $0.001 per share |
|
ONCY |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act
(§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.07. |
Submission of Matters to a Vote of Security Holders. |
On November 19, 2026, the Company held its
2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) at 4:00 p.m. Eastern Time by means of an online virtual
meeting platform. There were 131,120,719 shares of common stock outstanding on the record date. Stockholders representing 65,061,822,
or 49.61%, of the 131,120,719 votes outstanding were represented in person or by proxy constituting a quorum.
At the 2026 Annual Meeting, the following proposals
were approved: (i) the election of seven directors to hold office until the 2027 annual meeting; (ii) the ratification of the
appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31,
2026; and (iii) the advisory vote on the compensation of the Company’s named executive officers. The Board’s recommendation
to hold the advisory frequency vote on the compensation of the Company’s named executive officers every three years did not
receive a majority of the votes cast. The Board values the opinion of the Company’s stockholders and has taken into consideration
the recommendation of the Company’s stockholders to hold an advisory vote on executive compensation every year. After consideration,
the Board has determined, and believe it to be in the best interest of the Company, to hold an advisory vote on executive compensation
every three years, or until the Board otherwise determines that a different frequency for such advisor vote is in the best interest of
the stockholders of the Company. These proposals are described in detail in the Company’s definitive proxy statement on Schedule
14A for the 2026 Annual Meeting filed with the SEC on October 6, 2026.
Proposal 1
The votes with respect to the election of seven
directors to hold office until the 2027 annual meeting were as follows:
| Director | |
For | | |
% Voted For | | |
Withheld | | |
% Voted Withheld | | |
Broker Non- Votes | |
| Jared Kelly | |
| 21,465,185 | | |
| 89.54 | % | |
| 2,508,575 | | |
| 10.46 | % | |
| 41,088,062 | |
| Bernd R. Seizinger | |
| 21,380,239 | | |
| 89.18 | % | |
| 2,593,521 | | |
| 10.82 | % | |
| 41,088,062 | |
| Deborah M. Brown | |
| 21,572,684 | | |
| 89.98 | % | |
| 2,401,076 | | |
| 10.02 | % | |
| 41,088,062 | |
| James T. Parsons | |
| 20,724,255 | | |
| 86.45 | % | |
| 3,249,505 | | |
| 13.55 | % | |
| 41,088,062 | |
| Jonathan Rigby | |
| 21,506,444 | | |
| 89.71 | % | |
| 2,467,316 | | |
| 10.29 | % | |
| 41,088,062 | |
| Patricia S. Andrews | |
| 21,669,279 | | |
| 90.39 | % | |
| 2,304,481 | | |
| 9.61 | % | |
| 41,088,062 | |
| Stephen Glover | |
| 21,624,838 | | |
| 90.20 | % | |
| 2,348,922 | | |
| 9.80 | % | |
| 41,088,062 | |
Proposal 2
The votes with respect to the ratification of
KPMG LLP as the Company’s independent registered accounting firm for the year ending December 31, 2026, were as follows:
| Total Votes For | |
Total Votes Against | | |
Abstentions | | |
Broker Non-Votes | |
| 62,887,796 | |
| 1,694,520 | | |
| 479,506 | | |
| - | |
Proposal 3
The votes with respect to the advisory vote to
approve the compensation of the Company’s named executive officers were as follows:
| Total Votes For | |
Total Votes Against | | |
Abstentions | | |
Broker Non-Votes | |
| 13,559,766 | |
| 9,777,095 | | |
| 636,899 | | |
| 41,088,062 | |
Proposal 4
The votes with respect to the advisory vote on
the frequency of the advisory vote on the compensation of the Company’s named executive officers were as follows:
| 3 Years | |
2 Years | | |
1 Year | | |
Abstentions | | |
Broker Non-Votes | |
| 9,781,900 | |
| 1,485,942 | | |
| 11,319,330 | | |
| 1,386,588 | | |
| - | |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Date: November 20, 2026
| |
ONCOLYTICS BIOTECH INC. |
| |
|
| |
By: |
/s/ Kirk Look |
| |
Name: |
Kirk Look |
| |
Title: |
Chief Financial Officer |